Manulife Investment Management (M) Berhad has launched the Manulife Global Healthcare Fund (Fund).
The Fund provides an opportunity for Malaysian investors to contribute to the development of the global healthcare industry and capture future medium to long-term capital growth for healthcare-related companies worldwide.
The Fund is suitable for investors who seek capital appreciation, with a medium- to long-term investment horizon, and wish to seek investment exposure in healthcare-related companies globally.
It will invest at least 95 percent of the Fund’s Net Asset Value (NAV) in Share class I3 of Manulife Global Fund – Healthcare Fund (Target Fund).
The Target Fund capitalises on the healthcare sector’s growth potential and invests in diversified sub-sectoral positions to capture three global structural trends: aging demographics, innovations in medicine, and unmet medical needs.
The Fund’s remaining NAV will be in liquid assets. The Target Fund is managed by a well-resourced investment team from Manulife Investment Management with broad industry knowledge and an average of 27 years of investment management and healthcare experience.
The Target Fund also has a key feature of medium- to long-term investment with a high conviction portfolio, guided by a differentiated investment approach.
“We believe companies with products and services that were guided by unique principles should see unprecedented demand, such as innovative companies that offer ground-breaking medical advancements.
In fact, we have seen three secular trends that could create long-term opportunities for the sector – increasing medical needs as the world population ages and living longer, solving ongoing health issues and challenges, and striving for medical breakthroughs,” Jason Chong, Chief Executive Officer of Manulife Investment Management (M) Berhad said.
According to Ng Chze How, Head of Retail Wealth Distribution of Manulife Investment Management (M) Berhad, investors should consider adding diversity in their portfolio and pay closer attention to specific verticals in healthcare that can benefit from ongoing demographic and industry trends, despite the positive news of Covid-19 vaccines, which is expected to help bring the global economy to recovery in 2021.
“Based on market conditions, we seek to build a diversified portfolio of healthcare companies while ensuring active positions that are aligned with strength of conviction, intrinsic valuation, and appropriate risk parameters.
This can provide the potential long-term capital growth that investors seek from their investments, as well as contribute to medical innovations that benefit humanity.” he stated.
Notably, distribution of income by the Fund, if any, is incidental. It is available in A (RM-Hedged) class, with a minimum initial investment of RM1,000 and a minimum additional investment of RM100. The Fund is now available for subscription through the unit trust advisers of Manulife Investment Management (M) Berhad.
